Literature DB >> 29911112

Translational research and application of basic biology to clinical trial development in GI cancers.

Elizabeth Smyth1, Khurum Khan1, Nicola Valeri1,2.   

Abstract

Cancers of the gastrointestinal tract have limited available treatments and are often associated with a poor prognosis. Clinical trials and translational work associated with these trials provide the opportunity to increase understanding of the mechanisms of sensitivity and resistance to cytotoxic chemotherapy and targeted therapy in these diseases. In this review we discuss the rationale for intensive translational work within the context of academic clinical trials and the successes and challenges which have been associated with translational work at our institution over the past number of years. We reflect on tissue, plasma and radiological biomarker work including a novel patient derived organoid programme and discuss the iterative application of previous results to next generation trial design.

Entities:  

Keywords:  Gastrointestinal cancer; clinical trials; colorectal cancer (CRC); ctDNA; gastric cancer; liquid biopsy; next generation sequencing (NGS); translational

Year:  2018        PMID: 29911112      PMCID: PMC5985276          DOI: 10.21037/atm.2018.05.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  41 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

Review 3.  Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.

Authors:  K Polom; L Marano; D Marrelli; R De Luca; G Roviello; V Savelli; P Tan; F Roviello
Journal:  Br J Surg       Date:  2017-11-01       Impact factor: 6.939

4.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

5.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

6.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.

Authors:  Philipp M Kazmierczak; Egon Burian; Ralf Eschbach; Heidrun Hirner-Eppeneder; Matthias Moser; Lukas Havla; Michel Eisenblätter; Maximilian F Reiser; Konstantin Nikolaou; Clemens C Cyran
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

9.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Authors:  Georgios Vlachogiannis; Somaieh Hedayat; Alexandra Vatsiou; Yann Jamin; Javier Fernández-Mateos; Khurum Khan; Andrea Lampis; Katherine Eason; Ian Huntingford; Rosemary Burke; Mihaela Rata; Dow-Mu Koh; Nina Tunariu; David Collins; Sanna Hulkki-Wilson; Chanthirika Ragulan; Inmaculada Spiteri; Sing Yu Moorcraft; Ian Chau; Sheela Rao; David Watkins; Nicos Fotiadis; Maria Bali; Mahnaz Darvish-Damavandi; Hazel Lote; Zakaria Eltahir; Elizabeth C Smyth; Ruwaida Begum; Paul A Clarke; Jens C Hahne; Mitchell Dowsett; Johann de Bono; Paul Workman; Anguraj Sadanandam; Matteo Fassan; Owen J Sansom; Suzanne Eccles; Naureen Starling; Chiara Braconi; Andrea Sottoriva; Simon P Robinson; David Cunningham; Nicola Valeri
Journal:  Science       Date:  2018-02-23       Impact factor: 47.728

10.  Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.

Authors:  Fergus Noble; Luke Nolan; Adrian C Bateman; James P Byrne; Jamie J Kelly; Ian S Bailey; Donna M Sharland; Charlotte N Rees; Timothy J Iveson; Tim J Underwood; Andrew R Bateman
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

View more
  2 in total

Review 1.  Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Authors:  David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz
Journal:  Curr Gastroenterol Rep       Date:  2019-01-30

Review 2.  Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.

Authors:  Erika Durinikova; Kristi Buzo; Sabrina Arena
Journal:  J Exp Clin Cancer Res       Date:  2021-06-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.